Treating chronic obstructive pulmonary disease in people with type 2 diabetes
GLP-1 receptor agonists, DPP-4 inhibitors and SGLT-2 inhibitors are commonly prescribed antihyperglycaemic drugs, which are known for their favourable cardiovascular effects. However, according to Pradhan et al (2022), emerging research suggests that they may also benefit the respiratory system. There has been interest therefore in exploring whether or not these drugs could benefit the large amount of people who are living with the disabling lung condition, chronic obstructive pulmonary disease (COPD).
A new study published in the British Medical Journal has examined whether the use of the receptor agonist glucagon-like peptide 1 (GLP-1), dipeptidyl peptidase 4 (DPP-4) inhibitors, and sodium-glucose co-transporter-2 (SGLT-2) inhibitors, separately, are associated with a lower risk of COPD exacerbations among patients living with COPD and type 2 diabetes (Pradhan et al, 2022). This cohort was chosen as those with type 2 diabetes are at high risk of COPD-related morbidity and mortality (Castañ-Abad et al, 2020).
Register now to continue reading
Thank you for visiting Journal of Prescribing Practice and reading some of our peer-reviewed resources for prescribing professionals. To read more, please register today. You’ll enjoy the following great benefits:
Limited access to our clinical or professional articles
New content and clinical newsletter updates each month